Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2024/05/02 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Gabar Health Sciences Corp. | 82429-107 | TOPICAL | 5 mg in 1 g | 10/21/2023 | |
Eckson Labs LLC | 44118-701 | TOPICAL | 48 mg in 1 g | 3/30/2022 | |
Brava Pharmaceuticals, LLC | 57883-404 | TOPICAL | 48 mg in 1 g | 12/26/2019 | |
BioComp Pharma, Inc. | 44523-520 | TOPICAL | 50 mg in 1 g | 8/16/2023 | |
BioComp Pharma, Inc. | 44523-602 | TOPICAL | 50 mg in 1 g | 3/23/2023 | |
Acella Pharmaceuticals, LLC | 42192-133 | TOPICAL | 40 mg in 1 mL | 9/11/2018 | |
Deseret Biologicals, Inc. | 43742-2218 | ORAL | 30 [hp_X] in 1 mL | 5/27/2025 | |
SOHM, Inc | 50405-850 | TOPICAL | 50 mg in 1 g | 5/3/2023 | |
Bryant Ranch Prepack | 72162-2247 | TOPICAL | 40 mg in 1 mL | 1/30/2024 | |
Gabar Health Sciences Corp. | 82429-108 | TOPICAL | 2 mg in 1 g | 1/29/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
SINIX | terra botanica products ltd. | 02233367 | Liquid - Oral | 30 X | 5/25/1998 |
POSTACNE LOTION - 2% | dermik laboratories canada inc. | 02220369 | Lotion - Topical | 2 % | 11/19/1998 |
CATALIGO NO.1-LIQ | laboratoires holis inc. | 02132281 | Liquid - Oral | 5 D / ML | 12/31/1986 |
DIATHESIS I | bio active canada ltd. | 02233598 | Liquid - Oral | 12 X | 5/26/1998 |
OPI-BOSAN B58-LIQ | professional health products | 02157934 | Liquid - Oral | 6 D / ML | 12/31/1996 |
SORNIX | terra botanica products ltd. | 02233368 | Liquid - Oral | 30 X | 5/25/1998 |
HEEL 135 TAB | 01969234 | Tablet - Oral | 4 D / TAB | 12/31/1992 | |
CUTISITUM | 02236489 | Liquid - Oral | 10 D | 2/6/1998 | |
ANTI-ACNE FORMULA FOR MEN | clinique laboratories dist | 00729744 | Cream - Topical | 3.75 % | 12/31/1987 |
SASTID SOAP FOR STUBBORN ACNE | stiefel canada ulc | 00403598 | Soap Bar - Topical | 10 % | 12/31/1977 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.